Suppression of angiotensin converting enzyme 2, a host receptor for SARS-CoV-2 infection, using 5-aminolevulinic acid in vitro.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 01 11 2022
accepted: 22 01 2023
entrez: 9 2 2023
pubmed: 10 2 2023
medline: 14 2 2023
Statut: epublish

Résumé

Angiotensin converting enzyme 2 (ACE2), an entry receptor found on the surface of host cells, is believed to be detrimental to the infectious capability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientists have been working on finding a cure since its outbreak with limited success. In this study, we evaluated the potential of 5-aminolevulinic acid hydrochloride (ALA) in suppressing ACE2 expression of host cells. ACE2 expression and the production of intracellular porphyrins following ALA administration were carried out. We observed the reduction of ACE2 expression and intracellular porphyrins following ALA administration. ALA suppressed the ACE2 expression in host cells which might prevent binding of SARS-CoV-2 to host cells. Co-administration of ALA and sodium ferrous citrate (SFC) resulted in a further decrease in ACE2 expression and increase in intracellular heme level. This suggests that the suppression of ACE2 expression by ALA might occur through heme production. We found that the inhibition of heme oxygenase-1 (HO-1), which is involved in heme degradation, also resulted in decrease in ACE2 expression, suggesting a potential role of HO-1 in suppressing ACE2 as well. In conclusion, we speculate that ALA, together with SFC administration, might serve as a potential therapeutic approach in reducing SARS-CoV-2 infectivity through suppression of ACE2 expression.

Identifiants

pubmed: 36757984
doi: 10.1371/journal.pone.0281399
pii: PONE-D-22-30163
pmc: PMC9910746
doi:

Substances chimiques

Aminolevulinic Acid 88755TAZ87
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Porphyrins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0281399

Informations de copyright

Copyright: © 2023 Nara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

H.I., M.I. and M.N. are employees of SBI Pharmaceuticals Co., Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Diabetes Res. 2019 Nov 6;2019:4267357
pubmed: 31781665
Photodiagnosis Photodyn Ther. 2022 Dec;40:103055
pubmed: 35934181
Int Immunopharmacol. 2016 Aug;37:71-78
pubmed: 26643355
Nat Commun. 2022 Mar 17;13(1):1444
pubmed: 35301316
World J Gastroenterol. 2016 Jan 21;22(3):1289-96
pubmed: 26811665
Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200
pubmed: 25843912
Int J Clin Oncol. 2021 Jan;26(1):26-33
pubmed: 32875514
Photodiagnosis Photodyn Ther. 2020 Mar;29:101617
pubmed: 31857216
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199
Photodiagnosis Photodyn Ther. 2019 Sep;27:327-335
pubmed: 31252141
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Sci Rep. 2019 Jul 22;9(1):10549
pubmed: 31332208
FASEB J. 1988 Jul;2(10):2557-68
pubmed: 3290025
Sci Rep. 2021 Nov 2;11(1):21462
pubmed: 34728736
Int J Cancer. 2007 Feb 1;120(3):500-5
pubmed: 17066448
Int Immunopharmacol. 2011 Mar;11(3):358-65
pubmed: 21144919
Nat Med. 2018 Jun;24(6):802-813
pubmed: 29785027
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Sci Total Environ. 2020 Jul 10;725:138277
pubmed: 32278175
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Acta Neurochir (Wien). 2020 Apr;162(4):785-793
pubmed: 32034493
FEMS Microbiol Lett. 1995 May 1;128(2):195-200
pubmed: 7750738
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
Biochem Biophys Res Commun. 2021 Mar 19;545:203-207
pubmed: 33571909
J Photochem Photobiol B. 2021 May;218:112191
pubmed: 33862352
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Trop Med Health. 2022 Jan 7;50(1):6
pubmed: 34991723

Auteurs

Eriko Nara (E)

School of Life Science and Technology, Tokyo Institute of Technology, Midori-ku, Yokohama, Japan.

Hung Wei Lai (HW)

School of Life Science and Technology, Tokyo Institute of Technology, Midori-ku, Yokohama, Japan.

Hideo Imazato (H)

SBI Pharmaceuticals Co. Ltd., Minato-ku, Tokyo, Japan.

Masahiro Ishizuka (M)

SBI Pharmaceuticals Co. Ltd., Minato-ku, Tokyo, Japan.

Motowo Nakajima (M)

SBI Pharmaceuticals Co. Ltd., Minato-ku, Tokyo, Japan.

Shun-Ichiro Ogura (SI)

School of Life Science and Technology, Tokyo Institute of Technology, Midori-ku, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH